Primary ILM peeling prevents macula pucker development

Article

Primary peeling of the internal limiting membrane (ILM) successfully prevents the development of macula pucker and the full removal of all epiretinal membranes.

Primary peeling of the internal limiting membrane (ILM) successfully prevents the development of macula pucker and the full removal of all epiretinal membranes, claims a study in the journal Retina.

The investigation, led by Dr D. Odrobina, Klinika Okulistyczna, Poland, included of 84 patients who underwent retinectomy with silicone oil tamponade for retinal detachment caused by proliferative vitreoretinopathy.

Eyes were split into two groups with 33 eyes in group A and 51 eyes in group B. In group A the ILM was peeled and in group B the ILM was not peeled. The effect of ILM peeling for the prevention of macula pucker was determined by slit-lamp examination.

The first month after retinectomy revealed cases of extramacular epiretinal cellular proliferation in 3 eyes in group A and 3 eyes in group B. In the final follow-up there were no macular pucker cases in group A and 9 cases of macula pucker in group B.

Eyes with retinal detachment caused by proliferative vitreoretinopathy were successfully treated by retinectomy and silicone oil tamponade. Primary peeling of the ILM is a successful method of preventing the development of macula pucker.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.